Ghadeer K Dawwas, Ph.D.
Assistant ProfessorNashville , TN 37203
Dr. Dawwas holds MSc and PhD degrees in pharmacoepidemiology from the University of Florida, an MBA from Stratford University, and a bachelor’s in pharmacy from the University of Jordan. She completed her postdoctoral fellowship at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Dawwas is a pharmacoepidemiologist and her research program uses readily available healthcare data to provide stakeholders including patients, clinicians, payers, and policymakers with evidence on the risk/benefit tradeoffs of therapeutic alternatives to improve clinical decision-making. The major themes of her research center on the evaluation of anticoagulants, research methods, and the intersection of comparative effectiveness research and health policy. Her most notable contribution stems from the work that evaluated apixaban and rivaroxaban in patients with venous thromboembolism (VTE) that, among other evidence, led CVS Caremark to reverse its decision regarding the removal of apixaban from CVS preferred formulary list.
Dr. Dawwas' work resulted in notable peer-reviewed manuscripts published in Annals of Internal Medicine, Diabetes Care, and Lancet Hematology. Currently, she serves as the PI of two grants funded by the National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH) that aim to improve VTE treatment and prevention in populations under-represented or excluded from randomized clinical trials.
Dr. Dawwas is the recipient of several awards from national and international organizations including fellowships from the ASH and American Association of University Women (AAUW), Best Article of the Month by Emergency Medicine Reviews and Perspectives, Paper of the Year by American Association of Colleges of Pharmacy (ACCP), International Society for Pharmacoepidemiology (ISPE) Second Best Abstract Award, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Top Research Presentation, and Phi Kappa Phi Love of Learning Award.
Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases. Inflamm Bowel Dis [print-electronic]. 2023 Apr 4/12/2023; PMID: 37043675, PII: 7116272, DOI: 10.1093/ibd/izad053, ISSN: 1536-4844.
Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study. Ann Intern Med [print-electronic]. 2022 Nov; 175(11): 1506-14. PMID: 36252244, DOI: 10.7326/M22-0318, ISSN: 1539-3704.
Dawwas GK, Cuker A, Rothstein A, Hennessy S. Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. J Stroke Cerebrovasc Dis [print-electronic]. 2022 Oct; 31(10): 106700. PMID: 35964533, PII: S1052-3057(22)00394-9, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106700, ISSN: 1532-8511.
Dawwas GK, Barnes GD. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. Curr Cardiol Rep [print-electronic]. 2022 Jun; 24(6): 731-8. PMID: 35460473, PII: 10.1007/s11886-022-01690-9, DOI: 10.1007/s11886-022-01690-9, ISSN: 1534-3170.
Dawwas GK, Cuker A, Connors JM, Barnes GD. Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes [letter]. Am J Hematol [print-electronic]. 2022 May; 97(5): E173-E176-E176. PMID: 35147235, PMCID: PMC8986609, DOI: 10.1002/ajh.26494, ISSN: 1096-8652.
Dawwas GK, Hennessy S, Brensinger CM, Acton EK, Bilker WB, Chung S, Dublin S, Horn JR, Manis MM, Miano TA, Oslin DW, Pham Nguyen TP, Soprano SE, Wiebe DJ, Leonard CE. Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study. CNS Drugs [print-electronic]. 2022 Apr; 36(4): 389-400. PMID: 35249204, PMCID: PMC9375100, PII: 10.1007/s40263-022-00909-1, DOI: 10.1007/s40263-022-00909-1, ISSN: 1179-1934.
Dawwas GK, Flory JH, Hennessy S, Leonard CE, Lewis JD. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes Care. 2022 Apr 4/1/2022; 45(4): 919-27. PMID: 35147696, PMCID: PMC9114717, PII: 144557, DOI: 10.2337/dc21-2177, ISSN: 1935-5548.
Dawwas GK, Brensinger CM, Vajravelu RK, Wu Q, Kelly CR, Laine L, Wu GD, Lewis JD. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol [print-electronic]. 2022 Apr; 20(4): 806-816.e6-816.e6. PMID: 33307184, PMCID: PMC8184854, PII: S1542-3565(20)31642-6, DOI: 10.1016/j.cgh.2020.12.004, ISSN: 1542-7714.
Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med [print-electronic]. 2022 Jan; 175(1): 20-8. PMID: 34871048, DOI: 10.7326/M21-0717, ISSN: 1539-3704.
Dawwas GK, Hennessy S, Brensinger CM, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Aquilante CL, Kimmel SE, Leonard CE. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies. Clin Pharmacol Ther [print-electronic]. 2022 Jan; 111(1): 227-42. PMID: 34331322, PMCID: PMC9450482, DOI: 10.1002/cpt.2381, ISSN: 1532-6535.
Dawwas GK, Barnes GD, Dietrich E, Cuker A, Leonard CE, Genuardi MV, Lewis JD. Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. Am Heart J [print-electronic]. 2021 Dec; 242: 71-81. PMID: 34450051, PII: S0002-8703(21)00212-X, DOI: 10.1016/j.ahj.2021.08.014, ISSN: 1097-6744.
Dawwas GK, Barnes GD, Cuker A, Lewis JD. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation [letter]. Ann Intern Med. 2021 Oct; 174(10): 1490. PMID: 34662171, DOI: 10.7326/L21-0565, ISSN: 1539-3704.
Dawwas GK, Jajeh H, Shan M, Naegeli AN, Hunter T, Lewis JD. Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn's Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease. Crohns Colitis 360. 2021 Jul; 3(3): otab046. PMID: 36776663, PMCID: PMC9902261, PII: otab046, DOI: 10.1093/crocol/otab046, ISSN: 2631-827X.
Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. Ann Intern Med [print-electronic]. 2021 Jul; 174(7): 910-9. PMID: 33780291, DOI: 10.7326/M20-6194, ISSN: 1539-3704.
Dawwas GK, Dietrich E, Smith SM, Davis K, Park H. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. Clin Ther [print-electronic]. 2020 Sep; 42(9): e161-e176-e176. PMID: 32768247, PII: S0149-2918(20)30332-5, DOI: 10.1016/j.clinthera.2020.06.022, ISSN: 1879-114X.
Dawwas GK, Leonard CE, Garg M, Vouri SM, Smith SM, Flory JH, Genuardi MV, Park H. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes Obes Metab [print-electronic]. 2020 Apr; 22(4): 705-10. PMID: 31903713, DOI: 10.1111/dom.13949, ISSN: 1463-1326.
Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020 Jan 1/24/2020; 77(3): 188-95. PMID: 31974557, PII: 5715221, DOI: 10.1093/ajhp/zxz307, ISSN: 1535-2900.
Dawwas GK, Dietrich E, Winchester DE, Winterstein AG, Segal R, Park H. Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. Pharmacotherapy [print-electronic]. 2019 Sep; 39(9): 912-20. PMID: 31332815, DOI: 10.1002/phar.2311, ISSN: 1875-9114.
Dawwas GK, Brown J, Dietrich E, Park H. Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply [letter]. Lancet Haematol. 2019 Apr; 6(4): e181-e182-e182. PMID: 30926080, PII: S2352-3026(19)30049-3, DOI: 10.1016/S2352-3026(19)30049-3, ISSN: 2352-3026.
Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol [print-electronic]. 2019 Jan; 6(1): e20-e28-e28. PMID: 30558988, PII: S2352-3026(18)30191-1, DOI: 10.1016/S2352-3026(18)30191-1, ISSN: 2352-3026.
Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab [print-electronic]. 2019 Jan; 21(1): 28-36. PMID: 30039524, DOI: 10.1111/dom.13477, ISSN: 1463-1326.
Dawwas GK, Smith SM, Park H. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2018 Jul 7/17/2018; 17(1): 102. PMID: 30016946, PMCID: PMC6048850, PII: 10.1186/s12933-018-0746-4, DOI: 10.1186/s12933-018-0746-4, ISSN: 1475-2840.
| Posted | Position |
|---|---|
| 2/12/2024 | We are recruiting a second post-doc fellow to work on a grant funded by the American Society of Hematology that aims to evaluate the effectiveness and safety of anticoagulants. The position is available immediately. QUALIFICATIONS § PhD, ScD, MD, or PharmD with expertise in pharmacoepidemiology, health outcomes research, epidemiology, biostatistics, public health, or related field. § Understanding of epidemiology methods, study design, and data analysis. § Expertise with statistical software such as SAS. § Experience with claim databases such as MarketScan, Optum, Medicaid, or Medicare § Strong communication and analytical skills. Interested applicants should send a curriculum vitae and a cover letter to: Ghadeer K. Dawwas, PhD, MSc, MBA Assistant Professor of Medicine Division of Epidemiology Vanderbilt University School of Medicine
Ghadeer.Dawwas@vumc.org
|
| 12/4/2023 | POST-DOCTORAL RESEARCH FELLOWSHIP IN PHARMACOEPIDEMIOLOGY, COMPARATIVE EFFECTIVENESS AND SAFETY RESEARCH, AND REAL-WORLD EVIDENCE The Pharmacoepidemiology research group housed within VUMC Division of Epidemiology is looking for a highly motivated postdoctoral fellow to lead research projects funded by the National Institutes of Health focusing on evaluating the comparative effectiveness and safety of therapeutic alternatives using real-world data. The Fellow will work with a multidisciplinary research team and be mentored by Ghadeer Dawwas, PhD, MSc, MBA, Assistant Professor of Medicine: https://medicine.vumc.org/department-directory/Ghadeer-Dawwas. Fellowship start dates are flexible. The Fellow will be encouraged to lead their own research projects, write grants, communicate results at national and international conferences, and publish scientific findings. The division of pharmacoepidemiology places career mentoring as one of their top priorities and will provide the fellow with ample of opportunities for professional growth within and outside VUMC. QUALIFICATIONS * PhD, ScD, MD, or PharmD with expertise in pharmacoepidemiology, health outcomes research, epidemiology, biostatistics, public health, or related field. * Understanding of epidemiology methods, study design, and data analysis. * Expertise with statistical software such as SAS or R. * Experience with claim databases such as MarketScan, Optum, Medicaid, or Medicare * Strong communication and analytical skills. Please direct inquiries to Ghadeer.Dawwas@vumc.org. Applicants will be notified with the outcome after reviewing their application. Interested applicants should send a curriculum vitae and a cover letter to: Ghadeer K. Dawwas, Ph.D., MSc, MBA Assistant Professor of Medicine Division of Epidemiology Vanderbilt University School of Medicine
Ghadeer.Dawwas@vumc.org
|